56 results on '"Ambros, Peter F"'
Search Results
2. Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression
3. Recommendations for the Standardization of Bone Marrow Disease Assessment and Reporting in Children With Neuroblastoma on Behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group
4. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project
5. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group
6. Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human Schwann cell repair phenotype
7. The genetic tumor background is an important determinant for heterogeneous MYCN ‐amplified neuroblastoma
8. Identification of patient subgroups with markedly disparate rates ofMYCNamplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project
9. Significance of Clinical and Biologic Features in Stage 3 Neuroblastoma: A Report from the International Neuroblastoma Risk Group Project
10. Bone marrows from neuroblastoma patients: An excellent source for tumor genome analyses
11. Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project
12. Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project
13. Chromosomally integrated human herpesvirus 6: questions and answers
14. Free DNA in the blood serum can unmask MYCN amplified tumors
15. Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells
16. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project
17. Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics
18. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients
19. Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes
20. Visualization of episomal and integrated Epstein-Barr virus DNA by fiber fluorescencein situ hybridization
21. Clinical appearance of neuroblastoma 10 years after screening
22. Automatic telomere length measurements in interphase nuclei by IQ-FISH
23. Combined Immunofluorescence and FISH : New Prospects for Tumor Cell Detection/Identification
24. Neuroblastoma with focal MYCN amplification and bone marrow infiltration: A staging and treatment dilemma
25. Combined restriction landmark genomic scanning and virtual genome scans identify a novel human homeobox gene,ALX3,that is hypermethylated in neuroblastoma
26. Neuroblastoma with focalMYCN amplification and bone marrow infiltration: A staging and treatment dilemma
27. Prognostic significance of DNA di-tetraploidy in neuroblastoma
28. Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours
29. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines
30. Neuroblastoma cells provoke Schwann cell proliferation in vitro
31. Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas
32. Automatic detection and genetic profiling of disseminated neuroblastoma cells
33. Classification of isolated tumor cells and micrometastasis
34. Chromosomal regions involved in the pathogenesis of osteosarcomas
35. Combined111In-pentetreotide scintigraphy and123I-mIBG scintigraphy in neuroblastoma provides prognostic information
36. Quantitative analysis of disseminated tumor cells in the bone marrow by automated fluorescence image analysis
37. Biological aspects of neuroblastoma screening
38. Neuroblastoma screening for children: delay, repeat, or delete?
39. Neuroblastoma screening in infants postponed after the sixth month of age: A trial to reduce “overdiagnosis” and to detect cases with “unfavorable” biologic features
40. Demonstration of the translocation der(16)t(1;16)(q12;q11.2) in interphase nuclei of ewing tumors
41. Connatal localized neuroblastoma: The case to delay treatment
42. Detection of tumour cells in peripheral blood and bone marrow from ewing tumour patients by rt‐pcr
43. Detection of numerical and structural chromosome abnormalities in pediatric germ cell tumors by means of interphase cytogenetics
44. Interphase cytogenetic study of childhood acute lymphoblastic leukemia
45. Non-random integration of epstein-barr virus in lymphoblastoid cell lines
46. Neuroblastoma with N-myc amplification detected by urine: Mass screening in infants after the sixth month of life
47. Detection of 1p36 deletions in paraffin sections of neuroblastoma tissues
48. MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration
49. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.
50. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.